These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 8742095

  • 1. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G, Kolvenbag G, Nash A.
    Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
    [Abstract] [Full Text] [Related]

  • 2. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 3. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, Kennealey GT.
    Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
    [Abstract] [Full Text] [Related]

  • 4. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H, Hara I, Eto H.
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [Abstract] [Full Text] [Related]

  • 5. Maximal androgen blockade for advanced prostate cancer.
    Klotz L.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [Abstract] [Full Text] [Related]

  • 6. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ, Iversen P, Tammela T, Anderson J, Björk T, Kaisary AV, Morris T.
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [Abstract] [Full Text] [Related]

  • 7. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H.
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [Abstract] [Full Text] [Related]

  • 8. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I.
    J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708
    [Abstract] [Full Text] [Related]

  • 9. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
    Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B, Chen Y, Kolvenbag GJ.
    J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
    [Abstract] [Full Text] [Related]

  • 10. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y.
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [Abstract] [Full Text] [Related]

  • 11. A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
    Soloway MS, Schellhammer P, Sharifi R, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Eur Urol; 1996 Mar; 29 Suppl 2():105-9. PubMed ID: 8717471
    [Abstract] [Full Text] [Related]

  • 12. [Antiandrogen in prostate cancer].
    Maeda O, Usami M.
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract] [Full Text] [Related]

  • 13. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G.
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [Abstract] [Full Text] [Related]

  • 14. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
    Sciarra A, Cardi A, Di Silverio F.
    Urol Int; 2004 Jan; 72(2):91-8. PubMed ID: 14963347
    [Abstract] [Full Text] [Related]

  • 15. [The role of bicalutamide in the treatment of prostate cancer].
    Stav SY, Segal G.
    Harefuah; 2002 Apr; 141(4):379-83, 408, 407. PubMed ID: 12017896
    [Abstract] [Full Text] [Related]

  • 16. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P, Roder MA.
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
    [Abstract] [Full Text] [Related]

  • 17. [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
    Takada T, Ishizuya Y, Okada T, Ueda T, Inoue H, Hara T.
    Hinyokika Kiyo; 2011 Jun; 57(6):291-5. PubMed ID: 21795830
    [Abstract] [Full Text] [Related]

  • 18. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB, Ryan CW, Stadler WM, Vogelzang NJ.
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [Abstract] [Full Text] [Related]

  • 19. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 20. Controversies in the management of advanced prostate cancer.
    Tyrrell CJ.
    Br J Cancer; 1999 Jan; 79(1):146-55. PubMed ID: 10408706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.